Nerve growth factor in traumatic optic neuropathy

Descripción del Articulo

Traumatic optic neuropathy (TON) is an entity associated with facial and cranial trauma, and a leading cause of blindness. It is a severe complication of craniofacial trauma that directly (DTON) or indirectly (ITON) damages the optic nerve (ON) and whose global incidence is 0.7 to 2.5 %. The objecti...

Descripción completa

Detalles Bibliográficos
Autores: Zea Quispe, Justiniano Oseas, Orihuela Echavigurin, Roberto Michael, López Gonzales, Freddy Cristóbal
Formato: artículo
Fecha de Publicación:2023
Institución:Universidad de San Martín de Porres
Repositorio:Horizonte médico
Lenguaje:español
OAI Identifier:oai:horizontemedico.usmp.edu.pe:article/2098
Enlace del recurso:https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098
Nivel de acceso:acceso abierto
Materia:nerve growth factor
visual acuity
optic nerve diseases
wounds and injuries
factor de crecimiento nervioso
agudeza visual
neuropatía óptica
trauma
id REVHM_0f0306c7f8ed8379c7eadf38d0513330
oai_identifier_str oai:horizontemedico.usmp.edu.pe:article/2098
network_acronym_str REVHM
network_name_str Horizonte médico
repository_id_str
dc.title.none.fl_str_mv Nerve growth factor in traumatic optic neuropathy
Factor de crecimiento nervioso en neuropatía óptica traumática
title Nerve growth factor in traumatic optic neuropathy
spellingShingle Nerve growth factor in traumatic optic neuropathy
Zea Quispe, Justiniano Oseas
nerve growth factor
visual acuity
optic nerve diseases
wounds and injuries
factor de crecimiento nervioso
agudeza visual
neuropatía óptica
trauma
title_short Nerve growth factor in traumatic optic neuropathy
title_full Nerve growth factor in traumatic optic neuropathy
title_fullStr Nerve growth factor in traumatic optic neuropathy
title_full_unstemmed Nerve growth factor in traumatic optic neuropathy
title_sort Nerve growth factor in traumatic optic neuropathy
dc.creator.none.fl_str_mv Zea Quispe, Justiniano Oseas
Orihuela Echavigurin, Roberto Michael
López Gonzales, Freddy Cristóbal
author Zea Quispe, Justiniano Oseas
author_facet Zea Quispe, Justiniano Oseas
Orihuela Echavigurin, Roberto Michael
López Gonzales, Freddy Cristóbal
author_role author
author2 Orihuela Echavigurin, Roberto Michael
López Gonzales, Freddy Cristóbal
author2_role author
author
dc.subject.none.fl_str_mv nerve growth factor
visual acuity
optic nerve diseases
wounds and injuries
factor de crecimiento nervioso
agudeza visual
neuropatía óptica
trauma
topic nerve growth factor
visual acuity
optic nerve diseases
wounds and injuries
factor de crecimiento nervioso
agudeza visual
neuropatía óptica
trauma
description Traumatic optic neuropathy (TON) is an entity associated with facial and cranial trauma, and a leading cause of blindness. It is a severe complication of craniofacial trauma that directly (DTON) or indirectly (ITON) damages the optic nerve (ON) and whose global incidence is 0.7 to 2.5 %. The objective of this study is to present the case of a patient who suffered fromTON and, at the same time, an asymmetrical bilateral condition, and was treated with nerve growth factor (NGF). This drug was the first to be discovered and demonstrate efficacy in maintaining the survival of central and peripheral neurons and facilitating their growth, differentiation and regeneration. A 13-year-old male patient attended the emergency room of Instituto Nacional de Ciencias Neurológicas and was later followed up at the Neuro-Ophthalmology Service. He was diagnosed with post-traumatic amaurosis caused by traumatic brain injury and epidural hematoma, and received two treatment cycles of NGF. After the first treatment cycle, hyporeactivity of both eyes occurred. And, at the end of the second treatment cycle, visual acuity improved significantly. NGF has been approved and marketed in China since 2015 and is a product thathas demonstrated its efficacy and safety in several clinical trials. Therefore, this study aims to make NGF a promising ITON treatment; in that sense, further clinical research is needed in this particular case.
publishDate 2023
dc.date.none.fl_str_mv 2023-03-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098
10.24265/horizmed.2023.v23n1.09
url https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098
identifier_str_mv 10.24265/horizmed.2023.v23n1.09
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1421
https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1441
https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1460
dc.rights.none.fl_str_mv Derechos de autor 2023 Horizonte Médico (Lima)
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2023 Horizonte Médico (Lima)
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/xml
text/html
dc.publisher.none.fl_str_mv Universidad de San Martín de Porres. Facultad de Medicina Humana
publisher.none.fl_str_mv Universidad de San Martín de Porres. Facultad de Medicina Humana
dc.source.none.fl_str_mv Horizonte Médico (Lima); Vol. 23 No. 1 (2023): January-March; e2098
Horizonte Médico (Lima); Vol. 23 Núm. 1 (2023): Enero-Marzo; e2098
Horizonte Médico (Lima); v. 23 n. 1 (2023): Enero-Marzo; e2098
2227-3530
1727-558X
reponame:Horizonte médico
instname:Universidad de San Martín de Porres
instacron:USMP
instname_str Universidad de San Martín de Porres
instacron_str USMP
institution USMP
reponame_str Horizonte médico
collection Horizonte médico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1845989100401721344
spelling Nerve growth factor in traumatic optic neuropathyFactor de crecimiento nervioso en neuropatía óptica traumáticaZea Quispe, Justiniano Oseas Orihuela Echavigurin, Roberto Michael López Gonzales, Freddy Cristóbal nerve growth factorvisual acuityoptic nerve diseaseswounds and injuriesfactor de crecimiento nerviosoagudeza visualneuropatía ópticatraumaTraumatic optic neuropathy (TON) is an entity associated with facial and cranial trauma, and a leading cause of blindness. It is a severe complication of craniofacial trauma that directly (DTON) or indirectly (ITON) damages the optic nerve (ON) and whose global incidence is 0.7 to 2.5 %. The objective of this study is to present the case of a patient who suffered fromTON and, at the same time, an asymmetrical bilateral condition, and was treated with nerve growth factor (NGF). This drug was the first to be discovered and demonstrate efficacy in maintaining the survival of central and peripheral neurons and facilitating their growth, differentiation and regeneration. A 13-year-old male patient attended the emergency room of Instituto Nacional de Ciencias Neurológicas and was later followed up at the Neuro-Ophthalmology Service. He was diagnosed with post-traumatic amaurosis caused by traumatic brain injury and epidural hematoma, and received two treatment cycles of NGF. After the first treatment cycle, hyporeactivity of both eyes occurred. And, at the end of the second treatment cycle, visual acuity improved significantly. NGF has been approved and marketed in China since 2015 and is a product thathas demonstrated its efficacy and safety in several clinical trials. Therefore, this study aims to make NGF a promising ITON treatment; in that sense, further clinical research is needed in this particular case.La neuropatía óptica traumática (TON) es una entidad asociada al trauma facial y craneal, y constituye una causa importante para el desarrollo de la ceguera; es una complicación grave del trauma craneofacial que daña directa (dTON) o indirectamente (iTON) el nervio óptico (ON), cuya incidencia global de TON es de 0,7 a 2,5 %. El objetivo del presente estudio es presentar el caso de un paciente que padecía de TON y a la vez de una afección bilateral asimétrica, y que fue tratado con el factor de crecimiento nervioso mNGF. Este medicamento fue el primero que se descubrió y demostró eficacia en mantener la supervivencia de las neuronas centrales y periféricas y facilitar su crecimiento, diferenciación y regeneración. Se trata de un paciente de 13 años, sexo masculino, quien acude a la emergencia del Instituto Nacional de Ciencias Neurológicas y, posteriormente, su seguimiento clínico es por consultorio de Neuroftalmología, con un cuadrode amaurosis traumática, producto de un traumatismo encéfalo craneano con hematoma epidural, que recibió dos ciclos de tratamiento con factor de crecimiento nervioso. Luego del primer ciclo de tratamiento, se evidenció hiporreactividad de ambos ojos; al finalizar el segundo ciclo de tratamiento, se observó un aumento considerable de la agudeza visual. El mNGF está aprobado y comercializado en China desde el año 2015 y es un producto que ha demostrado su eficacia yseguridad en varios ensayos clínicos. Por ello, el presente estudio pretende convertir al factor de crecimiento nervioso como el tratamiento prometedor de iTON; en ese sentido, se necesita de amplias investigaciones clínicas en este caso enparticular.Universidad de San Martín de Porres. Facultad de Medicina Humana2023-03-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/xmltext/htmlhttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/209810.24265/horizmed.2023.v23n1.09Horizonte Médico (Lima); Vol. 23 No. 1 (2023): January-March; e2098Horizonte Médico (Lima); Vol. 23 Núm. 1 (2023): Enero-Marzo; e2098Horizonte Médico (Lima); v. 23 n. 1 (2023): Enero-Marzo; e20982227-35301727-558Xreponame:Horizonte médicoinstname:Universidad de San Martín de Porresinstacron:USMPspahttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1421https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1441https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1460Derechos de autor 2023 Horizonte Médico (Lima)https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:horizontemedico.usmp.edu.pe:article/20982023-03-03T14:48:39Z
score 13.37163
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).